Exicure Funding

Approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures . With this investment, the company has raised a total of approximately $31.5 million in this current round.

"Nucleic acid therapeutics hold great promise because they target the underlying genetic source of disease," said Dr. David Giljohann, Chief Executive Officer of Exicure. "Toxicity and delivery have been the primary challenges for companies seeking to use nucleic acids in drug development. Our SNA technology seeks to overcome these challenges and to change the cost curves and development timelines of highly targeted medicines. We are advancing a pipeline of drugs for a broad range of chronic conditions and orphan diseases in dermatology, ophthalmology, respiratory and gastric disorders, and solid tumors. We welcome this new round of investors in Exicure as they bring great insight into rapidly emerging markets for our products."

"As we look to the next generation of innovative pharmaceuticals, we clearly see a major role for nucleic acid therapies that regulate genes and enhance the immune system to combat disease," said Dr. Li You Xin, Senior Vice President and head of R&D of Luye Pharma Group. "The team at Exicure has made tremendous strides in unlocking the potential of these highly-targeted medicines.
"